Aurobindo Pharma Limited has announced the transfer of ownership of its Russian subsidiary, Auro Pharma LLC. The move involves transferring the entity from Auro Active Pharma Private Limited to Auropharm Overseas Limited, both wholly-owned subsidiaries. The transaction, approved by the board, is valued at approximately INR 29 crore in cash consideration. This internal reorganization aims to streamline the group’s holdings in its Russian operations.
Internal Reorganization of Russian Subsidiary
Aurobindo Pharma Limited has disclosed a significant internal reorganization involving its Russian operations. The company’s board of directors has approved the proposal to transfer the ownership of Auro Pharma LLC, Russia. This entity will move from one wholly-owned subsidiary, Auro Active Pharma Private Limited, to another, Auropharm Overseas Limited.
Transaction Details and Rationale
The transaction involves the transfer of the entire 100% stake in Auro Pharma LLC. The consideration for this transfer is a cash payment of approximately INR 29 crore, subject to adjustments agreed upon by the parties. The board of directors for the respective companies, as well as the main company, have given their approval for this strategic move. The stated purpose behind this internal reorganization is to streamline the group’s holdings of its Russian subsidiary.
The disclosure also clarifies that the transaction is between wholly-owned subsidiaries and is therefore exempt from certain SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as it is conducted at an arm’s length price.
Entity Background and Financials
Auro Pharma LLC, incorporated on July 24, 2023, in Russia, is primarily involved in the manufacturing and marketing of pharmaceutical products. Its turnover for the financial years 2023-24, 2024-25, and 2025-26 is reported as Nil. In contrast, its immediate holding company, Auroactive Pharma Private Limited, had a turnover of INR 701.3 million for the financial year ended March 31, 2026. Auropharm Overseas Limited also reported Nil turnover for the same period.
The completion of this share transfer is expected within 60-90 days, contingent upon customary corporate and transfer formalities. No specific governmental or regulatory approvals are required for this acquisition.
Source: BSE
